Developing novel anti-fibrotic therapeutics to modulate post-surgical wound healing in glaucoma: big potential for...

Area of Science:

• Ophthalmology
• Fibrosis Research
• Drug Development

Background:

• Ocular fibrosis causes significant visual impairment and blindness globally, representing a major unmet clinical need.
• Current treatments, mitomycin C and 5-fluorouracil, prevent post-surgical fibrosis but carry risks of tissue damage and infection.
• Glaucoma filtration surgery is a common procedure where post-operative fibrosis significantly impacts success rates.

Approach:

• This review explores novel small molecule therapeutics for preventing ocular fibrosis.
• It examines advancements in ophthalmic wound healing, including antibodies, RNAi, gene therapy, and nanoparticles.
• The review also covers drug delivery systems like liposomes and dendrimers for anti-fibrotic agents.

Key Points:

• Development of new anti-fibrotic agents is crucial for managing ocular fibrosis.
• Diverse therapeutic strategies are being investigated beyond traditional antimetabolites.
• Challenges include effective drug delivery, sustained action, and minimizing toxicity in the delicate ocular environment.

Conclusions:

• Novel therapeutic classes show promise in preventing post-surgical ocular fibrosis.
• Addressing drug delivery and toxicity is essential for clinical translation of new anti-fibrotic agents.
• Continued research into ophthalmic wound healing is vital to reduce visual impairment from fibrosis.